Abstract: Der vorzeitige Samenerguß gilt als eine der am stärksten verbreiteten sexuellen Fehlfunktionen des Mannes und bleibt dennoch weitestgehend unterdiagnostiziert und ungenügend behandelt. Während die tatsächliche Verbreitung der vorzeitigen Ejakulation schwer nachzuweisen ist, belegen epidemiologische Studien, daß sich die Zahl der darunter leidenden Männer zwischen 1 und 75 % bewegt. Tatsächlich ist die Erörterung der Verbreitung nur einer der Faktoren, die die Definition sowohl der Krankheit wie auch des Ausmaßes des Problems, das bis heute Zündstoff für Diskussionen und Auseinandersetzungen liefert, verschleiert. Das historische Fehlen einer Akzeptanz und Anerkennung einer neurobiologischen Komponente hat dazu geführt, daß der vorzeitige Samenerguß unter medizinischen Fachleuten kaum als echte Krankheit anerkannt wird. Obwohl die neurobiologische Ursache von vorzeitigem Samenerguß zunehmend Bestätigung findet, bleiben viele Zweifel bestehen. Dieser Artikel befaßt sich schwerpunktmäßig mit der Anatomie und Physiologie der Ejakulation. Weitere Arten von Ejakulationsstörungen werden ebenfalls besprochen.
Introduction
Ejaculation disorders, particularly premature ejaculation (PE), represent some of the most prevalent yet under-diagnosed male sexual dysfunctions. Historically, these conditions were often dismissed as purely psychological "performance" issues. However, recent research highlights a significant paradigm shift toward a neurobiological understanding, particularly regarding neurotransmitter imbalances. This paper synthesizes the physiological mechanisms and therapeutic landscape to provide clinicians with a structured framework for evidence-based treatment.
The Physiological Framework
To understand these disorders, clinicians utilize the Masters and Johnson sexual response cycle as a baseline. This model tracks the progression from initial arousal (Erregung) through the plateau phase to ejaculation and the subsequent refractory period (Refraktärphase).
A critical physiological distinction is made between emission and expulsion. Emission, the secretion of fluid into the urethra, is controlled by the sympathetic nervous system. Expulsion, the rhythmic ejection of semen, involves the pelvic floor muscles. This distinction is vital for diagnosing conditions like retrograde ejaculation, where fluid is diverted into the bladder rather than expelled.
Neurobiological and Psychogenic Factors
The "serotonin brake" hypothesis is central to modern understanding. Serotonin (5-HT) acts as a primary inhibitory neurotransmitter; the activation of specific receptors (5-HT1A and 5-HT2C) sets the ejaculatory threshold. PE is increasingly viewed as a potential dysfunction of this serotonergic system.
While neurobiology provides the foundation, psychological factors like performance anxiety and sexual inexperience often create secondary feedback loops that exacerbate the condition. Effective treatment must therefore address both organic and psychogenic roots through multi-modal approaches.
Clinical Management and Treatment
Epidemiological data suggests that approximately 30% of men globally suffer from PE. Treatment strategies have evolved to include:
- Pharmacotherapy: SSRIs (e.g., Paroxetine, Sertraline) are highly effective at extending Intravaginal Ejaculation Latency Time (IELT), though often used off-label. The field is moving toward "on-demand" dosing to minimize systemic side effects.
- Behavioral Therapy: Techniques such as the "Squeeze" or "Stop-Start" methods help patients manage arousal levels alongside medication.
- Specialized Interventions: For rarer conditions like anejaculation (often resulting from surgery or diabetes), vibrostimulation and electrostimulation show high success rates (35–100%) for sperm retrieval in reproductive contexts.
Challenges and Future Directions
Despite progress, significant hurdles remain. There is a lack of universally accepted medical definitions for "premature," making cross-study comparisons difficult. Furthermore, evidence for treating delayed ejaculation remains relatively weak compared to PE. Future work must focus on developing faster-acting, selective serotonin transporter inhibitors with fewer side effects to improve patient compliance and clinical outcomes.
Summary updated